Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

A Amy McLemore (1Moffitt Cancer Center, Tampa, United States) S Surendra Neupane (1Moffitt Cancer Center, Tampa, United States) Z Zena Komrokji (1Moffitt Cancer Center, Tampa, United States) M Maria Balasis (1Moffitt Cancer Center, Tampa, United States) T Traci Kruer (1Moffitt Cancer Center, Tampa, United States) U Umesh Padia (2Massachusetts Institute of Technology, Cambridge, United States) S Sean Murphy A Aline Renneville (3Gustave Roussy, Paris, France) N Nathalie Droin D Dorothée Selimoglu-Buet (3Gustave Roussy, Paris, France) M Miguel Martinez (4University of Florida, Gainesville, United States) C Chaomei Zhang T Tania Mesa (1Moffitt Cancer Center, Tampa, United States) S Sean Yoder D David Sallman (Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States) A Andrew Kuykendall (Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States) C Christopher Ryder (1Moffitt Cancer Center, Tampa, United States) R Rami Komrokji (Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States) M Mrinal Patnaik (5Mayo Clinic, Rochester, United States) M Meghan Ferrall-Fairbanks (4University of Florida, Gainesville, United States) R Regina Barzilay E Eric Solary (3Gustave Roussy, Paris, France) E Eric Padron (Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States)

Abstract

Abstract Background The expansion of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow is universally associated with adverse outcomes and disease progression in all chronic myeloid neoplasms, to include chronic myelomonocytic leukemia (CMML). However, HSPCs are a heterogeneous cellular compartment and the impact of its composition on clinical outcomes remains poorly defined. Single cell RNA-sequencing (scRNA-seq) represents an optimal strategy to annotate cellular composition but no large clinically annotated scRNA-seq datasets are currently available. To address this, we have embarked to generate a clinically annotated 500 patient CMML scRNA-seq atlas from CD34+ enriched BMNCs to establish among the largest clinically and genetically annotated single cell references for any chronic myeloid malignancy. Here we report the interim analysis of 113 clinically annotated cases that demonstrates massive reshaping of HSPC composition that is independently a predictor of overall survival. Methods Single-cell RNA expression profiling was performed on 113 CD34-enriched CMML BMNC samples using 10x Genomics GEM-X Universal 3' Gene Expression v4 (4-plex) chemistry. Libraries were sequenced on NovaSeq S4 flow cells in two runs, and data were processed using Cell Ranger to generate gene expression matrices. A total of 502,659 single cells from 113 samples were processed using Seurat. The upper threshold for gene count was defined as the mean number of detected genes plus two standard deviations data normalization was performed using the log-normalization method. Batch correction and integration were conducted with Harmony to mitigate technical variation across pools. Descriptive statistics were used to tabulate clinical and genetic parameters. KM curves, log-rank test, and cox regression were used to calculate survival, test for statistical differences, and perform multivariate analysis, respectively. Results To derive high resolution cell annotations, we employed the SingleR algorithm using a large hematopoietic reference of over 300,000 single cells (Zhang, X. Nature Immunology, 2024). Using this approach a diverse set of cell types were identified that included HSCs, 23 myeloid progenitors, 18 erythroid progenitors, and 18 lymphoid progenitors. This diverse cellular repertoire displayed massive reshaping relative to the normal CD34 enriched reference including a >53x expansion of multilineage GMPs and a >100x depletion of B-cell progenitors consistent with the known myeloid skewing seen in this disease. To understand whether expansion of specific progenitors was associated with outcomes we iteratively evaluated key progenitor populations and observed that expansions of HSC (HR 0.468 p<0.005) and MEP (HR 0.485, p<0.005) were associated with improved survival while GMP (HR 1.729, p=0.029) expansions were associated with inferior survival when using a cut point derived with a maximally selected ranks statistics approach. To achieve a more comprehensive metric of HSPC composition we explored GMP ratios to include GMP/HSC ratios and GMP/MEP ratios and observed that both were associated with inferior survival in univariate and multivariate when considering clinical and genetic features such as the CPSS-molecular prognostic score and FAB classification. When considering both GMP/HSC and GMP/MEP ratios in a multivariate model only GMP/MEP ratios and CPSS molecular remained independently prognostic. As an orthogonal approach, pseudotime projections were carried out using a reference map from Setty et al., 2019 to calculate differentiation potential and branch probabilities. This approach enabled both cell identity assignment and placement of cells along the hematopoietic differentiation trajectory. Samples were classified as monocyte-biased, MEP-biased, or normal-like, as previously described (Ferrall-Fairbanks et al. 2022) and demonstrated that increased GMP ratios are associated with a monocytic biased trajectory and that this trajectory is also associated with overall survival. Conclusion This study represents an interim analysis of among the largest scRNA-seq cohorts generated in chronic myeloid malignancies. This enabled us, for the first time, to demonstrate that HSPC composition is independently prognostic even when considering modern CMML prognostic models. As this cohort continues to increase, validation of these findings and examining the impact of therapy on HPSC composition in serial samples will be prioritized.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 3840-3840
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (23)

A

Amy McLemore

1Moffitt Cancer Center, Tampa, United States

S

Surendra Neupane

1Moffitt Cancer Center, Tampa, United States

Z

Zena Komrokji

1Moffitt Cancer Center, Tampa, United States

M

Maria Balasis

1Moffitt Cancer Center, Tampa, United States

T

Traci Kruer

1Moffitt Cancer Center, Tampa, United States

U

Umesh Padia

2Massachusetts Institute of Technology, Cambridge, United States

S

Sean Murphy

A

Aline Renneville

3Gustave Roussy, Paris, France

N

Nathalie Droin

D

Dorothée Selimoglu-Buet

3Gustave Roussy, Paris, France

M

Miguel Martinez

4University of Florida, Gainesville, United States

C

Chaomei Zhang

T

Tania Mesa

1Moffitt Cancer Center, Tampa, United States

S

Sean Yoder

D

David Sallman

Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States

A

Andrew Kuykendall

Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States

C

Christopher Ryder

1Moffitt Cancer Center, Tampa, United States

R

Rami Komrokji

Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States

M

Mrinal Patnaik

5Mayo Clinic, Rochester, United States

M

Meghan Ferrall-Fairbanks

4University of Florida, Gainesville, United States

R

Regina Barzilay

E

Eric Solary

3Gustave Roussy, Paris, France

E

Eric Padron

Moffitt Cancer Cancer and Research Institute, Tampa, Florida, United States